The pharmaceutical company expects to produce 700 million doses of its antigen this year.
The Modern pharmaceutical company presented this Thursday the accounts corresponding to the 2020 financial year, in which it also includes forecasts for this year. The company expects to generate revenues of 15,044 million euros (18,400 million dollars) in 2021 for the advance purchase agreements of its Covid-19 vaccine.
A figure that exceeds the one he gave Pfizer in its revenue forecasts for the coronavirus antigen: €12.4 billion in 2021 (15,000 million dollars).
According to the published statement, Moderna plans to produce 700 million doses -compared to the initial 600 million- and make capital investments to increase manufacturing capacity to 1.4 billion doses in 2022.
Regarding the income, the pharmaceutical company has achieved €432.44 billion (528,905 million dollars), compared to 9,952 million euros (12,173 million dollars) registered in 2019. Revenues driven by sales of its vaccine against Covid-19.
Despite this, Moderna has recorded losses of 610 million euros ($747 million) in 2020, compared to -420 million ($514 million) in 2019.
Vaccine against the South African strain
In addition to the results, the pharmaceutical company also announced this Thursday that it has already completed the development of the vaccine candidate against the South African variant of Covid-19 and has sent the material to the competent authorities. to start the clinical trial.
In a statement, the company explained that it has designed Strategies to deal with variants of the coronavirus. Thus, it will evaluate the effects of the booster dose, a combination of the booster dose with the original vaccine, and a third dose of the vaccine that is already on the market.